Novel Magnetic Resonance Detection and Profiling of Ovarian Cancer Across Specimens
Abstract
During this interim funding period, we have made progress identifying lead ovarian cancer markers for testing on human samples. We have also made progress optimizing the processing of ascites and peripheral blood and even enhanced the sensitivity and robustness of the assay in a manner that is background insensitive to minimize sample loss during purification. Collection of all samples has been completed and we are now poised to analyze the diagnostic performance of our markers and move on to the next stage of querying for pathway modulation and activity. This work is important because we have, for the first time, customized micro-nuclear magnetic resonance for a specific disease (in this, ovarian cancer) and have developed a novel method that allows for sensitive and robust detection in a manner that does not rely much on purification. While we wait the diagnostic performance of the selected markers, it is clear based on our recently published work that our assay will be superior to the gold standard of flow cytometry with respects to profiling cells with minimal purification using smaller number of cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA569516
Entities
People
- Ralph Weissleder
Organizations
- Massachusetts General Hospital